News
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.
16h
Zacks Investment Research on MSNSRPT Slides on Voluntary US Elevidys Shipment Pause Amid ScrutinyShares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will ...
U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.
U.S. stock indexes inched their way to more records Monday to kick off a week full of profit updates from big U.S. companies.
U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.
U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose ...
Asian shares are mixed and U.S. futures have edged higher after U.S. stocks logged their third straight winning week.
1d
InvestorsHub on MSNSarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular DystrophyShares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk. The Food and Drug Administration will request that the company voluntarily ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results